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Metabolic Concepts in Idiopathic Intracranial Hypertension
and Their Potential for Therapeutic Intervention
Catherine Hornby, BMedSc, Susan P. Mollan, FRCOphth, Hannah Botﬁeld, PhD,
Michael W. O’Reilly, MRCP, PhD, Alexandra J. Sinclair, MRCP, PhD
Background: Traditional risk factors associated with idio-
pathic intracranial hypertension (IIH) include obesity, weight
gain, and female sex. The incidence of IIH is increasing and
yet the underlying trigger and the fueling pathological
mechanisms are still poorly understood.
Evidence Acquisition: Review of ophthalmology, neurology,
general surgery, obesity, endocrinology, nutrition, and
neurosurgery literature was made.
Results: The facts that implicate sex and obesity in IIH and
headache are examined. The role of fat distribution in IIH is
questioned, and the concept of adipose tissue functioning as
an endocrine organ driving IIH is discussed. The impact of
androgen metabolism in IIH is reviewed as is the emerging
role of glucagon-like-peptide-1 analogues in modulating intra-
cranial pressure. This introduces the concept of developing
targeted disease-modifying therapeutic strategies for IIH.
Conclusions: This review will discuss the possible role of the
adipose/gut/brain metabolism axis in IIH and speculate how this
may impact the pathogenesis of IIH and therapeutic opportunities.
Journal of Neuro-Ophthalmology 2018;0:1–9
doi: 10.1097/WNO.0000000000000684
© 2018 The Author(s). Published by Wolters Kluwer Health, Inc.
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I diopathic intracranial hypertension (IIH) is a condition ofincreased intracranial pressure (ICP) of unknown etiology
(1). Clinicians often debate the principal pathogenic mecha-
nisms, but no unifying theory has yet emerged. Cerebrospinal
ﬂuid (CSF) dynamics (overproduction or underdrainage) is
likely a result of an initial trigger or ongoing insult. Cerebral
venous sinus stenosis may occur in IIH, although its role in the
disease pathogenesis is debated. Exploration of the well-known
associations of female sex, obesity, weight gain, and polycystic
ovary syndrome (PCOS) has led to the active investigation of
the role of adipose tissue, androgens, and gut peptides in mod-
ulating ICP in IIH. A pathological basis for IIH, which may
also contribute to headache in IIH, could potentially involve
how the gut/brain metabolism axis interacts. For IIH, these
newly described pathways could lead to targeted weight loss
therapies, such as customized bariatric surgery, or other novel
therapeutics such as glucagon-like-peptide-1 (GLP-1) receptor
agonists. This review will discuss the possible role of the adi-
pose/gut/brain metabolism axis in IIH and speculate how this
may impact pathogenesis and therapeutic opportunities.
THE EVIDENCE IMPLICATING SEX
AND OBESITY
IIH predominately affects women, with less than 10% of
affected patients being men (1–4). There also is an associ-
ation between IIH and obesity, as over 90% of patients are
obese (5). The incidence of IIH is rising and seems to be
increasing with the general trend of rising obesity rates (6),
with the age- and sex-adjusted annual incidence more than
doubling in the period between 2002 and 2014 compared
with 1990–2001 in 1 study in the United States increasing
from 1.0 to 2.8 per 100,000 (7). When stratiﬁed for repro-
ductive age, female sex, and weight, the incidence has been
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reported between 12 and 28/100,000 per year (8). The risk
of IIH also increases with increasing body mass index (BMI)
(8). The greater degree of weight gain the year before symp-
tom onset results in a greater risk of IIH. Weight loss has
been shown to result in clinical improvement in several
parameters, including reduction in ICP, papilledema, and
headache (9). However, for an individual patient, the
amount of weight modiﬁcation needed to put the disease
into remission varies, which raises a question of whether it is
the type of adipose tissue or its location that is more relevant
than the absolute amount of adipose tissue that is lost.
QUESTIONING THE ROLE OF
FAT DISTRIBUTION
There is a strong association between abdominal fat deposi-
tion and health outcomes, including an increased risk of type
2 diabetes, adverse cardiovascular effects, insulin resistance,
and dyslipidemia (10–12). The pattern of fat distribution in
patients with IIH may be of relevance. One long-standing
theory is that the mechanical effects of excessive abdominal
fat elevate intra-abdominal pressure, which increases intratho-
racic pressure and, thereby, increases cerebral venous pressure,
and, consequently ICP (13). However, this hypothesis would
not explain why only a proportion of all individuals with
obesity develop IIH. Some studies measuring waist–hip
ratios have reported increased lower-body fat in IIH as
opposed to centripetal obesity (4,14). The use of dual-
energy x-ray absorptiometry scanning, a validated accurate
method to deﬁne and quantify body fat deposition, revealed
that patients with IIH have a similar, centripetal fat distribu-
tion compared with simple obesity (15). Interestingly, in IIH,
truncal fat mass correlates with opening pressure on lumbar
puncture although BMI does not. However, we cannot
exclude a false negative error affecting these results (15). It
has also been noted that fat is preferentially lost from the
trunk compared with the limbs in patients with IIH under-
going therapeutic weight loss resulting in signiﬁcant reduction
of ICP. This potentially implies that truncal fat mass may be
pathogenic in IIH. It is also interesting to note that although
BMI does not correlate with LP pressure in patients with IIH,
there is a signiﬁcant correlation between BMI and LP pressure
in patients who do not have increased ICP disorders (16).
EARLY INDICATIONS THAT ADIPOSE
TISSUE IS THE ENDOCRINE ORGAN
DRIVING INTRACRANIAL HYPERTENSION
Adipose tissue functions as an endocrine organ, secreting
a myriad of factors including proinﬂammatory cytokines,
chemokines, adipokines, and hormones (17) that may be
involved in IIH pathogenesis. Of note, some reports have
indicated that the adipokine, leptin, is elevated in the serum
(18) and CSF of patients with IIH, independent of BMI,
compared with BMI-matched control subjects (19). There
was a correlation of leptin levels between CSF and serum in
patients with IIH. In addition, the increased CSF–serum
leptin ratios in patients with IIH compared with controls
suggest that transfer of leptin over the blood–brain barrier is
not impaired in IIH, in contrast to obesity. Leptin is
involved in hypothalamic control of satiety and weight
regulation (20), and typically low CSF leptin levels are
found in patients with obesity. It is, therefore, curious that
CSF leptin levels are high in IIH (consequently driving
hypothalamic satiety), yet those patients remain obese. This
has increased the possibility of hypothalamic leptin resis-
tance in IIH. Leptin receptors are localized to the choroid
plexus and contribute to leptin transport in to the CSF (21).
In addition, choroid plexus is the principle site for CSF
secretion. However, the inconsistent ﬁndings from research
in this area diminish the likelihood that leptin has a domi-
nant role in pathogenesis, but aberrant leptin signaling may
be a contributing factor for obesity in IIH (19).
Obesity is a chronic inﬂammatory condition and,
consequently, another theory is the possibility of pathogenic
inﬂammation causing IIH (22–24). Investigation of the
cytokine and chemokine proﬁles in both the serum and
CSF of patients with IIH has shown a signiﬁcantly
increased level of chemokine proﬁles in both the serum
and CSF of patients with IIH has shown a signiﬁcantly
increased level of the chemokine CCL2 in the CSF of pa-
tients with IIH compared with controls, whereas CCL8,
CCL7, and IL-1a were increased in the plasma in IIH,
but not signiﬁcantly (25). However, this study did not
use a control group that was well matched to the patients
with IIH as BMI of the IIH cohort was signiﬁcantly higher
than that of controls. Therefore, these ﬁndings could be
representative of the inﬂammatory proﬁle in obesity rather
than in IIH. In addition, there were no signiﬁcant differ-
ences in the levels of serum and CSF interleukin-8 (IL-8),
monocyte chemoattractant protein-1 (MCP-1), resistin
plasminogen activator inhibitor-1 (PAI-1), tissue necrosis
factor-a (TNF-a), and hepatocyte growth factor (25).
CSF IL-6 was also not signiﬁcantly different in patients with
IIH nor were CSF:serum cytokine ratios. However, others
have found a proinﬂammatory cytokine proﬁle in patients
with IIH, with signiﬁcant elevations in IL-2 and IL-17 in
the CSF of patients with IIH compared with controls with
other neurological conditions. There was no difference in
serum cytokine levels, but a potential confounder was that
the controls were not BMI matched with the patients with
IIH (26).
Obesity occurs in conditions with excess secretion of
glucocorticoids such as Cushing syndrome. Systemic levels
of cortisol are regulated by the hypothalamic–pituitary–
adrenal axis. At a tissue level, cortisol is regulated by the
enzyme 11b-hydroxysteroid dehydrogenase (11b-HSD).
11b-HSD type 1 (11b-HSD1) which converts inactive
cortisone into cortisol and is found in high levels in the liver
and adipose tissue (27). Mice overexpressing 11b-HSD1
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globally, or speciﬁcally in adipose tissue, have a metabolic
syndrome phenotype of obesity, dyslipidemia, and glucose
intolerance (28). In humans, obesity is associated with
normal systemic cortisol levels but dysregulated 11b-HSD1
activity in adipose tissue (29). The relationship between
glucocorticoids and IIH is somewhat more complicated, as
IIH may occur during withdrawal or replacement of
glucocorticoid therapy (30). Activity and expression of 11b-
HSD1 is especially high in fat and, interestingly, 11b-
HSD1 has been localized to the choroid plexus, where it
drives local cortisol production (31). Cortisol generation in
the choroid plexus is believed to drive epithelial sodium
transporters on the apical membrane of the choroid plexus
epithelial cells and establish an ionic gradient, promoting
CSF production. 11b-HSD1 may, therefore, have a key
role in inﬂuencing the regulation of CSF secretion, and thus
ICP. Preliminary studies in patients with IIH have dem-
onstrated that therapeutic weight loss causes a reduction in
global 11b-HSD1 activity, which correlates with the
reduction in ICP (32). The effects of 11 b-HSD1 inhibi-
tion in reducing ICP in patients with IIH is currently being
assessed in a randomized clinical trial (33).
POSTULATING THE ROLE OF ANDROGEN
METABOLISM IN
INTRACRANIAL HYPERTENSION
Polycystic ovary syndrome (PCOS) and IIH share many
overlapping clinical features. PCOS is the most common
endocrine condition in women of reproductive age, and
androgen excess is a cardinal deﬁning feature in most
diagnostic consensus criteria (34,35). The most severe clin-
ical and biochemical features of androgen excess in PCOS
are observed in the context of comorbid obesity (36). A
number of reports have found that the prevalence of PCOS
is signiﬁcantly higher in women with IIH women compared
with the general female population (up to 57% compared
with 5%–10%). However, these studies did not compare
cohorts matched for age and BMI and, consequently, this
could represent a chance association (37). It is possible that
obesity, often noted in women with PCOS, could represent
the pathogenic driver in those individuals with coexisting
IIH and PCOS. However, although PCOS is more com-
mon in women with obesity, it can also occur in women of
normal body weight, so the association of IIH and PCOS
may not be due to obesity alone. Of interest, the prevalence
of PCOS is reported as signiﬁcantly lower in female cohorts
with simple obesity (28.3% in 1 study) compared with the
incidence reported in patients with IIH (57%) (38).
It has been proposed that androgen excess may be a risk
factor in women with IIH, independent of obesity, and that
hyperandrogenism may play a pathophysiological role in
disease onset. One study found that androgen excess was
associated with a younger age at onset of IIH, but did not
correlate with BMI, waist-to-hip ratios, or duration of IIH
(39). Patients with IIH have increased adipose tissue, and
androgen activation in adipose tissue may be relevant to the
pathophysiology of IIH. Adipose tissue plays a major role in
peripheral androgen generation (40), and increased intra-
adipose androgen activation is observed even in women
with simple obesity (41).
Case reports of transgender patients undergoing female
to male gender reassignment provide important insights
into the role of androgens in IIH. Five case reports detail
that patients receiving testosterone injections subsequently
developed IIH, 4 of whom showed a temporal relationship
between commencement of testosterone and symptoms of
IIH (Table 1) (42–46). There needs to be caution when
interpreting these reports because confounders such as
weight gain may have inﬂuenced the development of
increased ICP. Further evaluation of the role of testosterone
in ICP regulation would be of great interest.
IIH in men, although uncommon, also provides insights
into the complex and potentially sexually dimorphic role
that androgens may play in this disorder. Men with
androgen deﬁciency may be at increased risk of IIH; case
reports of developing IIH after induction of hypogonadism
with androgen deprivation therapy for prostate cancer have
been reported (47). It also has been documented that men
with IIH are more likely to have symptoms of testosterone
deﬁciency, such as erectile dysfunction and reduced libido
(48).
We suggest that a pathophysiological window of abnor-
mal circulating androgen levels, with serum testosterone
concentrations at a level shared by men with androgen
deﬁciency and women with androgen excess, could increase
the risk of IIH. Sexually dimorphic associations of andro-
gens are well recognized. Metabolic diseases such as non-
alcoholic fatty liver disease and diabetes are noted to have
a sexually dimorphic relationship to androgens (49). In
these metabolic conditions, women with androgen excess
and men with androgen deﬁciency have an overlapping
constellation of adverse cardio-metabolic risk factors (50).
Circulating testosterone concentrations in women with
androgen excess may overlap with those of men with andro-
gen deﬁciency; at these serum concentrations, there is pref-
erential accumulation of visceral adiposity in both sexes and
metabolically deleterious loss of skeletal muscle bulk in men
(51).
Therefore, it is conceivable that IIH represents a distinct
neurological manifestation of this adverse metabolic phe-
notype with female androgen excess and male androgen
deﬁciency conferring a risk factor for the development of
IIH. Although female androgen excess and male hypogo-
nadism are associated with abdominal obesity, which could
be the trigger for IIH in these cases, it is also important to
note that severe hypogonadism, with low androgen levels,
can occur independently of obesity in men and remains
associated with increased cardiovascular and all causes of
mortality (52). Equally, women with PCOS and androgen
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TABLE 1. Reports of idiopathic intracranial hypertension in patients with sex reassignment
Author Year
Sex
Reassignment
Symptom Occurrence
in Relation
to Testosterone
Temporal
Relationship of
Testosterone to
IIH Onset Other Treatment Outcome
Hornby et al (46) 2017 FTM Symptoms correlate
with testosterone
commencing
Yes LP shunt. Remission of
increased
intracranial
pressure
Buchanan et al
(42)
2017 FTM Testosterone dose
increasing, weight
increasing
Yes Treated with reduced androgen dosage and
acetazolamide. Subsequent weight loss.
Androgens later re-introduced with no return of
symptoms.
Remission
Park et al (43) 2014 FTM Patient on
testosterone
Yes Longer acting testosterone decanoate
substituted for testosterone propionate,
which resulted in decreased testosterone
levels.
Coexisting acetazolamide
Remission
Mowl et al (44) 2009 FTM Patient on
testosterone
Yes Acetazolamide and decreased testosterone
dosage.
Successful weight loss.
At the time of publication, testosterone
dose was being titrated up.
Remission
Sheets et al (45) 2007 FTM Symptoms started
10 months after
discontinuing
testosterone
No Treated with acetazolamide initially. Remission
FTM, female to male; IIH, idiopathic intracranial hypertension; LP, lumboperitoneal.
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excess are at increased risk of metabolic complications, such
as nonalcoholic fatty liver disease, independent of obesity
(53). Further studies in men and women are needed to
understand these complex sexually dimorphic associations
and their relationship to IIH and ICP regulation in the
context of obesity.
There also is very limited understanding of the roles of
estrogen and progesterone in IIH (54,55). Studies to date
describing estrogen (estrone) and progesterone levels in the
CSF have been small (n = 7 and n = 15), lacking matched
control groups, and hampered through the use radioimmu-
noassays with a poor lower limit of detection. This has led
to levels of estrogens being inconsistently detected in the
CSF. Estrogen receptors are expressed in the choroid plexus
epithelial cells, however, and their potential involvement in
CSF secretion is an interesting avenue for future studies
(56,57).
The Emerging Role of Gut Peptides in
Modulating Intracranial Pressure
Glucagon-like peptide-1 (GLP-1) is a gut peptide secreted
by the distal small intestine in response to food intake and
synthesized in neurons of the solitary tract nucleus. GLP-1
stimulates glucose-dependent insulin secretion and inhibits
glucagon release, lowering blood glucose (58) and promot-
ing satiety and weight loss (59). GLP-1 mimetics are cur-
rently being used clinically to treat obesity and diabetes. In
addition, GLP-1 has effects on renal proximal tubule
sodium ion (Na+) secretion by reducing Na+ resorption into
the blood stream and increasing diuresis (60). In the brain,
CSF secretion by the choroid plexus epithelial cells is also
driven by the net movement of Na+ from the blood into the
cerebral ventricles. The localization of the receptor to the
choroid plexus (61,62) suggests that GLP-1 may be able to
modulate Na+ transport in the choroid plexus and, thereby,
CSF production. Recently, it was demonstrated that
exendin-4, which is a GLP-1 receptor agonist, also known
as exenatide, currently prescribed to treat obesity and dia-
betes, reduces Na+/K+ATPase activity a marker of CSF
secretion. Of note, exendin-4 dramatically reduced ICP in
rodents with increased ICP. Exendin-4 reduced ICP by
44% within 10 minutes of dosing. Not only did the treat-
ment effects last for at least 24 hours, cumulatively, the
doses lowered the baseline ICP (61). Although there is no
FIG. 1. Glucagon-like peptide 1 (GLP-1) mechanism of action in IIH. Normally GLP-1 (purple circles) is produced by L-cells in
the small intestine in response to food. GLP-1 mimetics are used to treat diabetes and obesity and are administered by
subcutaneous injection. GLP-1 mimetics could be beneﬁcial for patients with IIH as they act on the hypothalamus to reduce
food intake and on adipose tissue to increase lipolysis resulting in weight loss. In addition, GLP-1 mimetics bind to GLP-1
receptors (GLP-1R) on the choroid plexus, leading to a reduction in CSF secretion and ICP. CSF, cerebrospinal ﬂuid; ICP,
intracranial pressure; IIH, idiopathic intracranial hypertension.
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current evidence that gut neuropeptides or GLP-1 are
implicated in the pathogenesis of IIH, these studies do
highlight the therapeutic potential for GLP-1 receptor ago-
nist in the management of IIH.
DEVELOPING TARGETED DISEASE-
MODIFYING STRATEGIES FOR
INTRACRANIAL HYPERTENSION
Weight loss typically results in clinical resolution of IIH
(9,63,64). A large number of case reports discuss the use of
bariatric surgery as a treatment for IIH, reporting signiﬁcant
improvement of symptoms and clinical signs in most pa-
tients (65–71). The IIH weight study (IIH:WT) (72) ﬁn-
ished recruitment in April 2017 and will test the hypothesis
that bariatric surgery will be more beneﬁcial in the long
term for treating IIH compared with community weight
loss programs.
There are several bariatric surgical approaches, including
Roux-en-Y gastric bypass, laparoscopic adjustable gastric
banding, and laparoscopic sleeve gastrectomy. All 3 surgical
methods result in a greater degree of weight loss compared
with nonsurgical interventions (73). Reports of the effect of
bariatric surgery on outcomes such as diabetes, lipid proﬁle,
and blood pressure are variable. One study found remission
of type 2 diabetes in 28.6%–67.5% of patients after surgery
(depending on the procedure) (74). What is relevant is that
gastric bypass, in particular Roux-en-Y bypass, enhances
GLP-1 levels contributing to the beneﬁcial effects of bari-
atric surgery in diabetes (75). Given the emerging role of
gut peptides in modifying ICP, it is interesting to speculate
that bariatric surgery techniques that modify GLP-1 to the
greatest degree (Roux-en-Y bypass), may be most effective
in inducing IIH remission, not only by virtue of weight lost
but also because of the effect on gut peptides and potentially
altering in CSF secretion.
Future therapies would ideally modify CSF secretion to
control ICP but also induce weight loss. The novel data on
the properties of GLP-1 receptor agonist to reduce ICP (61)
may represent an important advance that would have these
properties. Exenatide, a synthetic version of exendin-4,
a GLP-1 receptor agonist, is widely used to treat diabetes
FIG. 2. Metabolic pathogenesis and treatment in IIH. IIH is most prevalent in obese women of childbearing age, similar to
migraine and polycystic ovary syndrome. A combination of dysregulated adipose tissue and hormones may be involved in IIH
pathogenesis. Weight loss through bariatric surgery and diet has been shown to improve IIH symptoms. GLP-1R agonists may
have additional beneﬁts for patients with IIH by directly affecting ICP and causing weight loss. GLP-1R, glucagon-like-peptide-
1 receptor; ICP, intracranial pressure; IIH, idiopathic intracranial hypertension.
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and obesity and has the potential to be repurposed for the
treatment of increased ICP (Fig. 1). Furthermore, exenatide
has received orphan drug designation for the treatment of
IIH from the European Medicines Agency and the US Food
and Drug Administration. A clinical trial is currently under-
way exploring the physiological effects of exenatide in
reducing ICP in a small cohort of active patients with IIH.
CONCLUSIONS
The emerging link between IIH and metabolism is
potentially important. The areas outlined in this review
start to establish a link between IIH and the concept of
metabolic dysregulation (Fig. 2).
The underlying pathophysiological mechanism of IIH
has yet to be established. However, the answer may lie in
the location and metabolic activity of the excessive adipose
tissue in these patients. Ongoing randomized controlled
trials will potentially provide data that will help uncover the
relationship between obesity, weight loss, and IIH (72).
Novel, in-vivo and in vitro data suggest that exenatide,
a GLP-1 receptor agonist, may represent an ideal therapy
for IIH through rapid reduction of CSF secretion at the
choroid plexus, lowering ICP in addition to its weight loss
properties. Expanding our knowledge of the metabolic
pathways involved in ICP regulation and IIH maybe an
important step for future research, which could lead to
the identiﬁcation of novel targeted therapies for patients
with IIH.
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